These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 20819423)

  • 1. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
    Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
    Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
    J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.
    Takeda R; Kamano T; Sakamoto K; Sugano M; Hosoda S; Watanabe T; Maeda T; Kojima Y
    J Int Med Res; 2006; 34(3):307-15. PubMed ID: 16866026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
    Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
    Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil pharmacogenomics: still rocking after all these years?
    Scartozzi M; Maccaroni E; Giampieri R; Pistelli M; Bittoni A; Del Prete M; Berardi R; Cascinu S
    Pharmacogenomics; 2011 Feb; 12(2):251-65. PubMed ID: 21332317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
    Gajjar KK; Vora HH; Kobawala TP; Trivedi TI; Ghosh NR
    Int J Biol Markers; 2018 May; 33(2):180-188. PubMed ID: 29799355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.
    Mazzuca F; Borro M; Botticelli A; Mazzotti E; Marchetti L; Gentile G; La Torre M; Lionetto L; Simmaco M; Marchetti P
    Oncotarget; 2016 Apr; 7(15):20612-20. PubMed ID: 26967565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of
    Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
    Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
    Rumiato E; Boldrin E; Amadori A; Saggioro D
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
    Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
    Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
    Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
    Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
    Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity].
    Terashima M
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1101-4. PubMed ID: 18633250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.